Literature DB >> 1997637

Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men.

B Berglund1, B Ekblom.   

Abstract

The aim of this study was to evaluate the effect of treatment with subcutaneous injections of recombinant human erythropoietin (rhEpo), 20-40 IU kg-1 body weight, 3 times a week, on resting blood pressure, blood pressure response during submaximal exercise, some haematological parameters, and subjective side-effects in 15 healthy male subjects. RhEpo increased both haemoglobin (Hb) concentration and haematocrit (Hct) significantly, the values for Hb being 152 +/- 4.2 g l-1 before treatment and 169 +/- 9.3 g l-1 (mean values +/- SD) after 6 weeks of rhEpo treatment (P less than 0.001). The corresponding values for Hct were 44.5 +/- 1.5% and 49.7 +/- 1.9% (P less than 0.001), respectively. The systolic and diastolic blood pressure values at rest were unchanged after rhEpo treatment. A marked increase in systolic blood pressure was observed during submaximal exercise at 200 W, the initial and final values being 177 +/- 14.2 mmHg and 191 +/- 19.5 mmHg (P less than 0.01), respectively. Heart rate during exercise at 200 W was significantly lower after rhEpo treatment than before it: 144 +/- 15 beats min-1 compared to 136 +/- 8 beats min-1 (P less than 0.001). The leucocyte count remained unchanged after rhEpo treatment, but there was a significant decrease (P less than 0.05) in the number of lymphocytes. Reticulocyte and platelet counts were unchanged. Serum (S) ferritin decreased from 87.3 +/- 41.8 mmol l-1 to 59.3 +/- 27.8 mmol l-1 after rhEpo treatment (P less than 0.001). Serum-Na, S-K, S-Ca, S-creatinine, S-bilirubin, S-aspartate aminotransferase (ASAT), S-alanine aminotransferase (ALAT), and S-lactate dehydrogenase (LD) were unchanged after rhEpo treatment. No subjective side-effects were reported. In conclusion, low doses of rhEpo increased Hb levels and Hct by more than 10% after 6 weeks. Blood pressure at rest was unchanged, but rhEpo induced a markedly accentuated blood pressure reaction during exercise. A minor decrease in the lymphocyte count was observed, but electrolyte and creatinine levels remained unchanged after rhEpo treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997637     DOI: 10.1111/j.1365-2796.1991.tb00319.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  26 in total

Review 1.  Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control.

Authors:  Emmanuelle Varlet-Marie; Aurélie Gaudard; Michel Audran; Francoise Bressolle
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

2.  The low intracellular oxygen tension during exercise is a function of limited oxygen supply and high mitochondrial oxygen affinity.

Authors:  F J Larsen; B Ekblom
Journal:  Eur J Appl Physiol       Date:  2012-03-24       Impact factor: 3.078

Review 3.  Performance-enhancing substances in sports: a review of the literature.

Authors:  Amit Momaya; Marc Fawal; Reed Estes
Journal:  Sports Med       Date:  2015-04       Impact factor: 11.136

4.  Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity.

Authors:  J J Thomsen; R L Rentsch; P Robach; J A L Calbet; R Boushel; P Rasmussen; C Juel; C Lundby
Journal:  Eur J Appl Physiol       Date:  2007-08-01       Impact factor: 3.078

5.  Individual variation in the erythropoietic response to altitude training in elite junior swimmers.

Authors:  B Friedmann; F Frese; E Menold; F Kauper; J Jost; P Bärtsch
Journal:  Br J Sports Med       Date:  2005-03       Impact factor: 13.800

Review 6.  Maximal oxygen consumption in healthy humans: theories and facts.

Authors:  Guido Ferretti
Journal:  Eur J Appl Physiol       Date:  2014-07-02       Impact factor: 3.078

7.  Influence of recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics during exercise in humans.

Authors:  Daryl P Wilkerson; Jörn Rittweger; Nicolas J A Berger; Patrick F Naish; Andrew M Jones
Journal:  J Physiol       Date:  2005-08-04       Impact factor: 5.182

8.  RhEPO improves time to exhaustion by non-hematopoietic factors in humans.

Authors:  Simon Annaheim; Matthias Jacob; Alexander Krafft; Christian Breymann; Markus Rehm; Urs Boutellier
Journal:  Eur J Appl Physiol       Date:  2016-01-04       Impact factor: 3.078

9.  Comparison of a direct and indirect population pharmacodynamic model: application to recombinant human erythropoietin in athletes.

Authors:  F Bressolle; M Audran; R Gareau; T N Pham; R Gomeni
Journal:  J Pharmacokinet Biopharm       Date:  1997-06

10.  Gene therapy for long-term expression of erythropoietin in rats.

Authors:  W R Osborne; N Ramesh; S Lau; M M Clowes; D C Dale; A W Clowes
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.